Better Therapeutics, Inc. · OTC:BTTX
Better Therapeutics — Technical Presentation (December 2022)
30 slides from Better Therapeutics's technical presentation, Dec 12, 2022
Slide 1: LivVita Liver Health Feasibility Study Topline Data
DECEMBER 8, 2022 LivVita Liver Health Feasibility Study Topline Data Better+ T HERA PEU TICS
Slide 2: Disclaimer
Disclaimer This presentation (“Presentation”) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (“BetterTX” or the “Company”) nor any of its respective affiliates nor any of its or their control persons, of
Slide 3: Better Therapeutics: Pioneering prescription digital therapeutics for cardiometabolic diseases
Better therapeutics Pioneering Prescription digital therapeutics for cardiometabolic diseases
Slide 4: Contents
Contents better NAFLD/NASH Overview LivVita Topline Results conclusions Next Steps
Slide 5: NAFLD includes a spectrum of conditions rooted in unhealthy lifestyle behaviors
Non Alcoholic fatty liver Disease (NAFLD) includes a spectrum of conditions rooted in unhealthy lifestyle behaviors Fatty liver/ NASH+ Hepatocellular Cirrhosis NAFL Fibrosis Carcinoma Obesity Type 2 Diabetes Dyslipidemia Other factors Fat Fat plus Scar tissue Cancer Accumulation Inflammation, Replac
Slide 6: NAFLD is at epidemic levels in the United States
NAFLD is at epidemic levels in the United states and is leading cause of liver transplantation1 30%of adults in US have NAFLD 5% of adult in us have NASH Better 6
Slide 7: NAFLD and NASH prevalence projected to increase significantly
NAFLD and NASH prevalence projected to increase significantly2 with a growing proportion of NAFLD patient progressing to NASh Cases in millions 110 82.5 55 27.5 0 2015 2030 NAFLD 2015 2030 NASH Better 7
Slide 8: No FDA approved pharmacological agents for NAFLD or NASH
At present, despite billions invested, there are no FDA approved pharmacological agents for the treatment of NAFLD or NASH And leading candidates have frequent side effects Diarrhea Nausea Vomitting Itching Pemvidutide3 GLP1jglucagon dual receptor agonist 22% 52% 9% Phase1b Efruxifermin4 Fibroblast
Slide 9: Unmet needs in NAFLD/NASH require non-pharmacological therapies
We believe that addressing the unmet needs in NAFLD/NASH requ1res non-pharmacological therapies Qualities of an ideal new therapy in NAFLD Addresses full breadth of modifiable behavioral root causes Safe and well-tolerated Readily accessible, convenient and desired by patients Improves liver fat, gl
Slide 10: Contents
Contents NAFLD/NASH Overview LivVita Study Desingn Livvita Topline Results Conclusions Next Steps better 10
Slide 11: LivVita Study designed to assess efficacy and safety in NAFLD/NASH
LivVita Study was designed to assess potential for both efficacy and safety in NAFLD and/or NASH Partnered with leading specialty liver health clinic—Arizona Liver Heath—to design study and recruit diverse set of participants in 2 sites BT’s cardiometabolic Cognitive Behavioral Therapy (CBT) researc
Slide 12: LivVita Study Design and Participant Flow
LivVita Study Study Design and Participant Flow 35 screened Kev Inclusion Criteria 7i djd meet Criteria Q|. did nQt complete enrollment before it closed Confirmed diagnosis of NAFLD or NASH Ages 18-75 years Possession of a smartphone capable of running BT app 22 passed screening BMI > 30kg/m2 Eligib
Slide 13: LivVita Study Topline Key Endpoints
LivVita Study Topline Key Endpoints Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF): A specialized type of MRI that provides the most validated and reproducible non-invasive quantitative measure of liver fat Alanine Transaminase (ALT): An enzyme produced by liver cells. ALT blood l
Slide 14: Contents
NAFLD/NASH Overview LivVita Study Design Contents • LivVita Topline Results Conclusions Next Steps
Slide 15: Diverse set of patients recruited from specialty liver clinics in Arizona
Diverse set of patients recruited from 2 specialty liver clinics in Arizona Baseline characteristics represent commonly occurring cardiometabolic conditions in patients with NAFLD and NASH _ x > x Safety Population Parameter / Category (n=22) Age (mean) 48 yrs % Female 77% % Non-white 47% % Hispanic
Slide 16: Primary endpoint MRI-PDFF showed significant reductions in liver fat
The primary endpoint, MRI-PDFF, showed positive signal with statistically significant reductions in liver fat (p = 0.01)
Slide 17: Percent Change in MRI-PDFF
Percent Change in MRI-PDFF Intent-to-Treat Population “ â– -16% 18 Relative Reduction u. § 1 -11 -tl -12 -12 1R fl B a -16 _17 -is 0-26 L—so -64% Relative Reduction -70 ‘64 ALT results showed statistically significant reductions in marker of liver damage (p = 0.002)
Slide 18: FAST Score results showed significant reductions in NASH risk
FAST Score results showed statistically significant reductions in NASH Risk (p = 0.006)
Slide 19: FAST Score results showed significant reductions in NASH risk
FAST Score results showed statistically significant reductions in NASH Risk
Slide 20: CAP and Weight Change showed significant reductions
CAP and Weight Change showed statistically significant reductions in markers of liver damage Change in CAP Score Change in Weight A = -19 dB/m (-6%) p= 0.021 A = -7 lbs (-3% TBW) p = 0.008
Slide 21: Patient-reported weight showed gradual and steady improvements
Trending average change in patient-reported weight showed gradual and steady improvements, with no clear peak
Slide 22: Dose response between CBT engagement and liver health biomarkers
Dose response demonstrated positive relationship between CBT engagement and improvements in liver health biomarkers Low Use of Behavior Therapy High Use of Behavior Therapy < 13 Lessons completed >= 13 lessons completed
Slide 23: Safety data: no device related adverse events
Safety data revealed no device related adverse events (AEs) were experienced BT’s CBT was generally well-tolerated with few overall AEs reported over 3-month period Safety Population (n=22) Number of subjects who Subjects Events .... . .. . . . /ozx Mild Moderate Severe experienced: n (%) n An Adver
Slide 24: Patient engagement and satisfaction exceeded benchmarks
During 90 days of use, patient engagement and satisfaction significantly exceeded benchmarks for consumer health & wellness apps8>9. Notable Quality of Life improvements also reported10 94% 2.2 +75 Percentage of subjects Average added Healthy IMPS Score after 90 days using the app in Week 12 Days/mo
Slide 25: Contents
Contents LivVita Topline Results • Conclusions Next Steps NAFLD/NASH Overview LivVita Study Design
Slide 26: LivVita Study demonstrated clear potential for response with no safety concerns
LivVita Study demonstrated clear potential for response, with no safety related concerns observed, supporting our hypothesis and research platform Consistent improvements in MRI-PDFF and broad range of liver biomarkers found, with notable changes in ALT and FAST scores; improvements are consistent w
Slide 27: Naim Alkhouri, MD
Naim Alkhouri, MD Director of the Fatty Liver Program Arizona
Slide 28: Contents
Contents NAFLD/NASH Overview LivVita Study Design LivVita Topline Results Conclusions Next Steps
Slide 29: Next Steps
Next Steps • Submit manuscript for peer-reviewed publication _ Submit application to FDA for Breakthrough Device Designation and commence discussions on pivotal study design _ Consider partnership opportunities to accelerate development of BT’s NAFLD/NASH specific PDT
Slide 30: References
References Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020 May;158(7):18511864. doi: 10.1053/j.gastro.2020.01.052. Epub 2020 Feb 13. PMID: 32061595. Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018). Modeling the epi
Better Therapeutics — Technical Presentation (December 2022) on 6ix